Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
AstraZeneca
Merck
Daiichi Sankyo
Teva
Queensland Health
Covington
Mallinckrodt
McKinsey

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,149,477

« Back to Dashboard

Which drugs does patent 9,149,477 protect, and when does it expire?

Patent 9,149,477 protects ZYDELIG and is included in one NDA.

This patent has twenty-six patent family members in eighteen countries.
Summary for Patent: 9,149,477
Title:5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
Abstract: Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below: ##STR00001##
Inventor(s): Kesicki; Edward A. (Bothell, WA), Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Bellevue, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Puri; Kamal Deep (Lynnwood, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA)
Assignee: ICOS Corporation (Indianapolis, IN)
Application Number:14/284,331
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,149,477

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial INHIBITION ON PI3K KINASE ➤ Try a Free Trial
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial INHIBITION ON PI3K KINASE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,149,477

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,586,597 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta ➤ Try a Free Trial
8,779,131 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta ➤ Try a Free Trial
8,980,901 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Try a Free Trial
7,932,260 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,149,477

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005245875 ➤ Try a Free Trial
Australia 2009230739 ➤ Try a Free Trial
Canada 2566609 ➤ Try a Free Trial
China 101031569 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Colorcon
Julphar
Citi
Fuji
Teva
Harvard Business School
Cerilliant
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.